Table 2.
Summary of sensitivity and specificity of cobas® TV/MG compared with a composite reference
| Specimen type | N | Sensitivity | 95% CI | Specificity | 95% CI | Prevalence based on CR |
|---|---|---|---|---|---|---|
| U | 412 | 100% (25/25) | 86.3–100% | 99.7% (386/387) | 98.6–100% | 6.1% (25/412) |
| VS | 412 | 100% (25/25) | 86.3–100% | 99.7% (386/387) | 98.6–100% | 6.1% (25/412) |
| VS-CC | 222 | 100% (14/14) | 76.8–100% | 100% (208/208) | 98.2–100% | 6.3% (14/222) |
| VS-SC | 190 | 100% (11/11) | 71.5–100% | 99.4% (178/179) | 96.9–100% | 5.8% (11/190) |
| ES | 412 | 100% (22/22) | 84.6–100% | 99.2% (387/390) | 97.8–99.8% | 5.3% (22/412) |
| PC | 412 | 100% (23/23) | 85.2–100% | 99.5% (387/389) | 98.2–99.8% | 5.6% (23/412) |
| Total female | 1648 | 100% (95/95) | 96.9–100% | 99.5% (1546/1553) | 99.2–99.8% | 5.8% (95/1648) |
Abbreviations: CC, clinician-collected; CI, confidence interval; CR, composite reference; ES, endocervical swabs; PC, cervical specimens collected in PreservCyt® Solution; SC, self-collected; TV, Trichomonas vaginalis; U, urine; VS, vaginal swabs.